Efficacy and safety of risankizumab in psoriasis patients who failed anti‐IL ‐17, anti‐12/23 and/or anti IL ‐23: Preliminary data of a real‐life 16‐week retrospective study

Up until now, real‐life experiences on the efficacy of risankizumab in patients who had previously failed anti‐IL17, anti‐IL12/23 or anti‐IL23 inhibitor are not reported. We carried out a single‐center, retrospective study, to evaluate the efficacy, safety and tolerability of patients under risankizumab who previously failed anti‐IL17, anti‐IL12/23, or anti‐IL23 inhibitors in a real‐life setting. A total of eight patients were enrolled (four men and four women, mean age 45.8 ± 14.3 years). Five of them (62.5%) had received ustekinumab, seven (87.5%) at least one anti‐IL17, and only one (12.5%) patient guselkumab. Secukinumab had been used in five (62.5%) cases, and ixekizumab in four (50.0%). Baseline mean PASI and BSA were 11.9 ± 5.5, and 22.9 ± 13.1, respectively, and 3.3 ± 1.7 and 7.5 ± 5 ( P  < .001 and P  < .01) at week 16. Mean baseline NAPSI (18.0 ± 8.5) reduced to 7 ± 1.4 at week 16. Palmo‐plantar and scalp area showed a reduction of 67.5% and 99.9% at week 16, respectively. No AEs was reported. Real‐life preliminary data show risankizumab as a promising therapeutic option in patients who failed anti‐IL‐17, anti‐IL12/23 and even the other anti‐IL‐23 counterpart, guselkumab.